Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704.

The pharmacogenomics journal - 1 Oct 2012

Farrell J J, Bae K, Wong J, Guha C, Dicker A P, Elsaleh H

Abstract excerpt

The aim of this study is to validate the prognostic and predictive value of the non-synonymous cytidine deaminase (CDA) Lys²⁷Gln polymorphism for hematological toxicity and survival using a randomized phase III adjuvant trial (Radiation Therapy Oncology Group (RTOG) 9704) in pancreatic cancer in which one treatment arm received gemcitabine. CDA is involved in gemcitabine inactivation, and there is conflicting...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Pharmacological
Share to Cytidine Deaminase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Deoxycytidine

Share to Disease-Free Survival

Share to Fluorouracil

Share to Gemcitabine

Share to Neoplasm Staging

Share to Pancreatic Neoplasms

Source

Identifiers

PMID: 21625252
DOI: 10.1038/tpj.2011.22

Genes

CDA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cytidine deaminase single-nucleotide polymorphism is predictive of toxicity from gemcitabine in patients with pancreatic cancer: RTOG 9704.PMID 21625252Read ↗

Cytidine deaminase polymorphism predicts toxicity of gemcitabine-based chemotherapy.Semantic proximity Read ↗

Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity.Semantic proximity Read ↗

Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer.Semantic proximity Read ↗

The impact of CDA A79C gene polymorphisms on the response and hematologic toxicity in gemcitabine-treated patients: a meta-analysis.Semantic proximity Read ↗

A genome-wide association study identifies four genetic markers for hematological toxicities in cancer patients receiving gemcitabine therapy.Semantic proximity Read ↗

Prediction of a side effect and efficacy of adjuvant chemotherapy with gemcitabine for post operative patient of pancreatic cancer by a genetic polymorphism analysis.Semantic proximity Read ↗

Cytidine deaminase 435C>T polymorphism relates to gemcitabine-platinum efficacy and hematological toxicity in Chinese non-small-cell lung cancer patients.Semantic proximity Read ↗

Effect of genetic polymorphisms on therapeutic response and clinical outcomes in pancreatic cancer patients treated with gemcitabine.Semantic proximity Read ↗

Correlation between cytidine deaminase genotype and gemcitabine deamination in blood samples.Semantic proximity Read ↗

dCK Expression and Gene Polymorphism With Gemcitabine Chemosensitivity in Patients With Pancreatic Ductal Adenocarcinoma: A Strobe-Compliant Observational Study.Semantic proximity Read ↗

Relationship between single nucleotide polymorphisms in the deoxycytidine kinase gene and chemosensitivity of gemcitabine in six pancreatic cancer cell lines.Semantic proximity Read ↗

Identification and analysis of single-nucleotide polymorphisms in the gemcitabine pharmacologic pathway.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.